TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01391455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolation of the spermatic cord from mesh
Description: The spermatic cord is isolated from the mesh employed to repair an inguinal hernia following standard open repair.
Study: NCT04446299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowel Prep
Description: Orally ingested liquid bowel preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bowel Prep
Description: Orally ingested liquid bowel preparation
Study: NCT03322397

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Focused Acts of Kindness Intervention
Description: Participants engage in positive behaviors by completing acts of kindness for themselves three times per week. These acts should require effort and be outside of an individual's normal routine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other-Focused Acts of Kindness Intervention
Description: Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Daily Reports
Description: Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
Study: NCT02813863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03087708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxegol
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxegol
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00929136

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: USP endotoxin
Description: Continuous intra-arterial infusion
Study: NCT00618813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study: NCT01150604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help cognitive-behavioral online course
Description: A self-help online course based on cognitive behavioral therapy for major depression.
Study: NCT04054739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training
Description: intervention with robot-assisted gait training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill gait training
Description: intervention with treadmill gait training
Study: NCT03221660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F-Composite 2 system
Description: Procedures will be done using local anesthesia (if the patients wants that). The cavity is prepared according to the principles of the adhesive technique. First the adhesive will be applied and polymerized, afterwards the flowable resin-based restorative material will be applied and polymerized and then the sculptable resin-based restorative material will be applied and polymerized; all materials will be light-cured within short time with an experimental curing light.
Study: NCT00453661

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Intervention Group:~Cancer Screening Assessment (CSA) questionnaire 45-60 minutes annually for 4 years + Exit Questionnaire at end of study.~Comparison Group:~Exit Questionnaire only.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Intervention Group:~Cancer Screening Assessment (CSA) questionnaire 45-60 minutes annually for 4 years + Exit Questionnaire at end of study.~Comparison Group:~Exit Questionnaire only.

Intervention type: BEHAVIORAL
Intervention: Patient Navigator (PN)
Description: Staff member, called patient navigator (PN), who assist with medical care and/or screenings, questionnaires.
Study: NCT01194414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab SC
Description: Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab SC
Description: Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab SC
Description: Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab IV
Description: Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab IV
Description: Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab IV
Description: Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to tocilizumab SC
Description: Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to tocilizumab SC
Description: Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to tocilizumab IV
Description: Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to tocilizumab IV
Description: Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Description: stable dose as prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Description: stable dose as prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Description: stable dose as prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Description: stable dose as prescribed
Study: NCT02525952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatectomy
Description: Surgical removal of all lesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatectomy
Description: Surgical removal of all lesions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Transarterial chemoembolization with lipiodol and pirarubicin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Transarterial chemoembolization with lipiodol and pirarubicin
Study: NCT03015623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBI-101
Description: SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBI-101
Description: SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham control is an FDA-approved plasmapheresis device, without MSCs, which is integrated into a Continuous Renal Replacement Therapy circuit.
Study: NCT01080612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 330 mg pregabalin controlled release
Description: A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 330 mg pregabalin controlled release
Description: A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 330 mg pregabalin controlled release
Description: A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal

Intervention type: DRUG
Group type: OTHER
Intervention: 300 mg pregabalin immediate release
Description: A single dose of 300 mg immediate release capsule will be administered in the fasted state
Study: NCT00995605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMAP102
Description: AMAP102 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMAP102
Description: AMAP102 or Placebo
Study: NCT06116760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio-visual training
Description: 90 min/day x 10 days. Participants are seated in front of a 2 m × 2 m training board, at a distance of 1.2 m, in a dimly lit room. The board features 48 red light-emitting diodes (LED, diameter 1 cm, luminance 90 cd m2), distributed in six horizontal rows (eight lights per row). Forty-eight piezoelectric loudspeakers (0.4 W, 8Ω) are located above each light, producing a white-noise (80 dB, duration 100 ms).~Spatio-temporally congruent, cross-modal, audio-visual stimuli are presented at one out of 48 possible positions on the board. Participants are instructed to look at the fixation point - at the center of the apparatus - and to move their eyes to detect the presence of the visual stimulus (duration=100 ms) by pressing right button of a wireless mouse.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Audio-visual training
Description: 90 min/day x 10 days. Participants are seated in front of a 2 m × 2 m training board, at a distance of 1.2 m, in a dimly lit room. The board features 48 red light-emitting diodes (LED, diameter 1 cm, luminance 90 cd m2), distributed in six horizontal rows (eight lights per row). Forty-eight piezoelectric loudspeakers (0.4 W, 8Ω) are located above each light, producing a white-noise (80 dB, duration 100 ms).~Spatio-temporally congruent, cross-modal, audio-visual stimuli are presented at one out of 48 possible positions on the board. Participants are instructed to look at the fixation point - at the center of the apparatus - and to move their eyes to detect the presence of the visual stimulus (duration=100 ms) by pressing right button of a wireless mouse.
Study: NCT01016197

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extensor tendon repair
Description: Surgical repair of extensor tendon with bone anchor and splinting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mallet splint for 4 weeks
Description: The patient will wear a mallet splint for fours weeks and then mobilise their finger.
Study: NCT02228200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led care
Description: The nurse-led care consisted of a pre-chemotherapy nursing consultation and telephone follow-up sessions during chemotherapy. The nursing consultation was on the day of the first cycle before drug administration. It included: history review, overall status evaluation, need and problem assessment, information provision, psychological support, and referral. The telephone follow-up sessions were delivered within one week after the 1st, 2nd, 4th, and 6th, and 8th cycle. A telephone follow-up session included: (i) The overall status assessment and problem triage; (ii) Care delivery based on problem severity; (iii) Evaluation of the change of the problems on the following telephone call.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Routine care includes: (1) Brief education on possible side-effects and coping skills before chemotherapy; (2) Care on chemotherapy day: vital sign assessment, casual communication between nurses and patients, video about chemotherapy and side effects management. (3) Care in chemotherapy intervals: hotline for patients when they have health problems at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routine care includes: (1) Brief education on possible side-effects and coping skills before chemotherapy; (2) Care on chemotherapy day: vital sign assessment, casual communication between nurses and patients, video about chemotherapy and side effects management. (3) Care in chemotherapy intervals: hotline for patients when they have health problems at home.
Study: NCT01378637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES- Leg treatment
Description: 30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.
Study: NCT04145557

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: diode laser 980nm
Description: Procedure: Periodontal therapy with laser Scaling, root planning, oral hygiene instruction and diode laser 980nm treatment of periodontal pockets

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: scaling root planing
Description: scaling and root planing
Study: NCT02124330

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: montmorillonite 5 g
Description: 5g montmorillonite + 15 g protein (ratio 1:3)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: montmorillonite 3 g
Description: 3g MONT+ 15 g protein (ratio 1:5)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Montmorillonite 1 g
Description: 1g MONT+ 15 g protein (ratio 1:15)
Study: NCT00571948

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: more meat and a vegetable oil rich in omega-3 fatty acids
Description: The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.~The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: more meat and a vegetable oil rich in omega-3 fatty acids
Description: The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.~The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Babyfood with usual meat content and corn oil
Description: The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Babyfood with usual meat content and corn oil
Description: The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid
Study: NCT04112784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00039
Description: Noninvasive pulse oximeter sensor
Study: NCT01938456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Biconvex film coated oral tablets for once daily use with unit dosage strength of 0.5mg and 2.0 mg for dose level of 2.0mg, 1.5mg, 1.0mg, and 0.5mg
Study: NCT04159922

Intervention type: OTHER
Intervention: questionnaire
Description: Bortner self questionnaire: 14 items Cohen PSS Perceived Stress scale: 10 items quality of life scale: 32 items depression scale: 14 items
Study: NCT03432117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed respiratory rehabilitation
Description: There are 6 step-exercise presented in the application and initial target of exercise will be set according to subject condition. After subject completes targeted exercise, next step will be started.
Study: NCT01938456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Yellow or brownish yellow solution for injections with unit dosage strength of 20mg and 80 mg for intravenous infusion once every 3 weeks over at least one-hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Clear and colorless solution for once daily sub-cutaneous injection with unit dosage strength of 75 micrograms (mcg) for dose level of 50 mcg/meter\^2 or 75 mcg/body
Study: NCT04138121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound scan of the cricothyroid membrane
Study: NCT04510012

Intervention type: OTHER
Intervention: Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
Description: Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.

Intervention type: OTHER
Intervention: Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
Description: Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.

Intervention type: OTHER
Intervention: Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
Description: Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
Study: NCT03704467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: Participants received 90 milligrams per square meter (mg/m\^2) of M6620, intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m\^2, or 40 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620. Thereafter, avelumab 800 mg intravenously on Day 1 of every two weeks as a maintenance mono-therapy until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants received carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.
Study: NCT00283452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone counseling with written materials
Description: Participation in phone/mail counseling to maintain physical activity
Study: NCT01691209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoenix (BAY81-2996)
Description: Topical formulation applied to the skin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Hydrocortison cream
Description: 1% Hydrocortison cream applied to the skin
Study: NCT03231605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Vaccinating two Hepatitis A Vaccines separately in 18-24 months Children based on the grouping result .

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A Vaccine
Description: Vaccinating two Hepatitis A Vaccines separately in 18-24 months Children based on the grouping result .
Study: NCT03092921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Mask Seal
Description: Investigative Mask Seal to be used for OSA therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Mask
Description: Investigative Mask to be used for OSA therapy
Study: NCT02745444

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: low-calorie formula diet

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: protein-restricted diet
Study: NCT00967590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5036505
Description: 380mg iv infusion once weekly for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: iv infusion once weekly for 8 weeks
Study: NCT03228927

Intervention type: OTHER
Intervention: comparison of twin A to twin B
Description: Comparison of Twin A to Twin B

Intervention type: OTHER
Intervention: comparison of twin A to twin B
Description: Comparison of Twin A to Twin B